Literature DB >> 21986842

Response to salvage therapies and outcome in patients with multiple myeloma relapsing after pomalidomide therapy.

S Sinha, M Lacy, J Mikhael, S Hayman, F Buadi, K Detweiler-Short, A Dispenzieri, M Gertz, D Dingli, S V Rajkumar, S K Kumar.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21986842     DOI： 10.1038/leu.2011.279

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  9 in total

1.  MicroC(3): an ex vivo microfluidic cis-coculture assay to test chemosensitivity and resistance of patient multiple myeloma cells.

Authors:  Chorom Pak; Natalie S Callander; Edmond W K Young; Benjamin Titz; KyungMann Kim; Sandeep Saha; Kenny Chng; Fotis Asimakopoulos; David J Beebe; Shigeki Miyamoto
Journal:  Integr Biol (Camb)       Date:  2015-05-22       Impact factor: 2.192

2.  Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib.

Authors:  Paul G Richardson; David Siegel; Rachid Baz; Susan L Kelley; Nikhil C Munshi; Jacob Laubach; Daniel Sullivan; Melissa Alsina; Robert Schlossman; Irene M Ghobrial; Deborah Doss; Nora Loughney; Laura McBride; Elizabeth Bilotti; Palka Anand; Lisa Nardelli; Sandra Wear; Gail Larkins; Min Chen; Mohamad H Zaki; Christian Jacques; Kenneth C Anderson
Journal:  Blood       Date:  2012-12-14       Impact factor: 22.113

3.  Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1.

Authors:  Paul G Richardson; Todd M Zimmerman; Craig C Hofmeister; Moshe Talpaz; Asher A Chanan-Khan; Jonathan L Kaufman; Jacob P Laubach; Dharminder Chauhan; Andrzej J Jakubowiak; Steven Reich; Mohit Trikha; Kenneth C Anderson
Journal:  Blood       Date:  2016-03-23       Impact factor: 22.113

4.  Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma.

Authors:  S V Rajkumar; V Gupta; R Fonseca; A Dispenzieri; W I Gonsalves; D Larson; R P Ketterling; J A Lust; R A Kyle; S K Kumar
Journal:  Leukemia       Date:  2013-03-21       Impact factor: 11.528

5.  Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma.

Authors:  A A Chanan-Khan; A Swaika; A Paulus; S K Kumar; J R Mikhael; S V Rajkumar; A Dispenzieri; M Q Lacy
Journal:  Blood Cancer J       Date:  2013-09-06       Impact factor: 11.037

6.  Phase I study of KW-2478, a novel Hsp90 inhibitor, in patients with B-cell malignancies.

Authors:  K Yong; J Cavet; P Johnson; G Morgan; C Williams; D Nakashima; S Akinaga; H Oakervee; J Cavenagh
Journal:  Br J Cancer       Date:  2015-12-22       Impact factor: 7.640

7.  Phase I Study of Anti-GM2 Ganglioside Monoclonal Antibody BIW-8962 as Monotherapy in Patients with Previously Treated Multiple Myeloma.

Authors:  Rachid C Baz; Jeffrey A Zonder; Cristina Gasparetto; Frederic J Reu; Vincent Strout
Journal:  Oncol Ther       Date:  2016-11-02

8.  A phase I/II study of KW-2478, an Hsp90 inhibitor, in combination with bortezomib in patients with relapsed/refractory multiple myeloma.

Authors:  J Cavenagh; H Oakervee; P Baetiong-Caguioa; F Davies; M Gharibo; N Rabin; M Kurman; B Novak; N Shiraishi; D Nakashima; S Akinaga; K Yong
Journal:  Br J Cancer       Date:  2017-09-05       Impact factor: 7.640

Review 9.  Salvage therapy of multiple myeloma: the new generation drugs.

Authors:  Alessandra Romano; Concetta Conticello; Maide Cavalli; Calogero Vetro; Cosimo Di Raimondo; Valentina Di Martina; Elena Schinocca; Alessia La Fauci; Nunziatina Laura Parrinello; Annalisa Chiarenza; Francesco Di Raimondo
Journal:  Biomed Res Int       Date:  2014-05-19       Impact factor: 3.411
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.